Advancing Mass Spectrometry-Based Large-Cohort Proteomics for
Precision Medicine

Thursday, October 18, 2018

8 am PT, 11 am ET, 1700 CET

Large cohort studies are essential to the discovery of protein biomarkers, and their validation is indispensable to clinical utility. High-throughput and deep-proteome profiling for these studies are necessary, but they also need to generate reproducible results across different laboratories in a longitudinal mode. A high-throughput analytical workflow using high resolution MS1-based quantitative data-independent acquisition (HRMS1–DIA) mass spectrometry was standardized with well-defined experimental steps and systematically applied to a set of test samples. This Clinical OMICs webinar will highlight the objectives and outcome of this study:
  • Study design to ensure benchmarking across multiple Cancer Moonshot sites worldwide utilizing similar instrument platforms, procedures, and software.
  • Development and implementation of test standards and a HRMS1–DIA mass spectrometry method.
  • Results of the study that demonstrate stability and reproducibility of a label-free quantitative workflow with 24/7 operation mode for seven consecutive days.
  • The multi-site study also extended to a set of ovarian cancer tissue de-identified specimens for demonstrating the performance of HRMS1-DIA workflow solution in the real clinical researches.
For Research Use Only. Not for use in diagnostic procedures

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.?


Thomas Conrads, Ph.D.
Associate Director of Scientific Technologies
Inova Schar Cancer Institute
View Biography
Yue Xuan, Ph.D.
Senior Global Product Marketing Manager for Precision Medicine
Thermo Fisher Scientific
View Biography

Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)